NAD+ IV lounges in the Philippines: does the marketing match human evidence?

TL;DR

• NAD+ helps cells handle energy and enzyme reactions, but that basic role does not show that an IV session creates more energy, slower aging, or better recovery in a person.¹
• The best-known direct IV pilot tracked NAD+ through blood and urine in eight healthy men; it measured metabolic handling, not the wellness outcomes featured in many marketing messages.²
• Human studies of oral NAD+ precursors often move blood biomarkers, yet changes in cognition, fatigue, sleep, mood, and other functional outcomes have been uneven or absent.³
• A U.S. FDA warning about unsuitable ingredients and reported reactions shows why sterile-product quality deserves separate attention from any debate about effectiveness.⁴

In the Philippines, an IV lounge can wrap a complex molecule in a simple promise: sharper thinking, steadier energy, faster recovery, or “anti-aging.” The human record asks more exact questions.⁵ What entered the bloodstream?⁶ What changed on a laboratory test?⁷ What did people actually feel or do better?⁸ Keeping those questions separate gives Filipino readers a fairer way to read the pitch.

Start with the claim, not the molecule

NAD+ is a coenzyme, which means it helps other reactions happen inside cells.¹ It is involved in energy metabolism and several enzyme systems.¹ That makes it biologically important, but importance is not the same as proof that extra NAD+ creates a wellness result.¹

Marketing often moves across three steps without showing the joins.⁵ First, NAD+ matters in cells.¹ Second, an intervention changes NAD+ or a related metabolite in blood.³ Third, a person is said to gain energy, focus, recovery, or slower aging.⁵ Human research must test that third step with a clear outcome, comparator, and follow-up.⁵ A biochemical explanation can justify a study; it cannot supply the study’s answer.³

NAD+ is named here only as the neutral catalog reference below.

What the direct IV pilot actually measured

The widely cited 2019 infusion pilot was small and focused on metabolic fate.² Eight healthy men received NAD+ over six hours, while three received saline.² Researchers collected blood and urine across an eight-hour window.² They were not testing a lounge-style promise about focus, vitality, athletic recovery, or biological age.²

Plasma NAD+ and the measured metabolites did not rise during the first two hours.⁶ By six hours, urinary NAD+ and methyl nicotinamide had increased.⁶ The researchers interpreted this pattern as rapid removal and breakdown during the early part of the infusion.⁶

That is useful pharmacokinetic information: it describes where a substance or its by-products appear over time.⁶ It does not show that participants became more energetic, thought more clearly, recovered faster, or aged more slowly.²

A higher biomarker is not a felt benefit

The distinction becomes clearer in research on oral NAD+ precursors such as NR and NMN.³ These are related compounds that the body can use in NAD+ metabolism, but they are not the same intervention as intravenous NAD+.³ Route, compound, population, and study length all matter.³

A 2026 systematic review found that oral NR and NMN often changed circulating or cellular NAD-related measures.³ Results for physical function, metabolism, blood vessels, and other healthspan outcomes were heterogeneous, often null, or limited to particular endpoints.³ The review classified the direct IV pilot as pharmacokinetic context rather than a wellness outcomes trial.⁵

This creates a practical reading rule.⁵ “Raises NAD+” is a laboratory statement.³ “Improves energy” or “slows aging” is a person-level claim that needs its own measured human outcome.⁵

Cognition and fatigue need their own tests

Two randomized precursor trials show why a biomarker cannot stand in for experience.³ In one 10-week pilot, 20 older adults with mild cognitive impairment received oral NR or placebo.⁷ Blood NAD+ rose 2.6-fold in the NR group, but cognition did not change.⁷ The study was small and involved a specific clinical population.⁷

Another trial enrolled 58 adults with long COVID and followed them for 24 weeks.⁸ Oral NR raised NAD+, yet the randomized comparison did not find significant gains in cognition, fatigue, sleep, or mood.⁸ Dropout was substantial, and the researchers also reported exploratory within-group patterns.⁸ Those exploratory patterns do not replace the planned placebo comparison.⁸

Neither trial tested an IV lounge session.⁷ Together, they illustrate a narrower point: biochemical target engagement and a noticeable human benefit are different endpoints.³

A positive hospital study has firm borders

The direct IV record is not limited to healthy volunteers.⁹ A 2025 single-center trial enrolled 180 adults with heart failure caused by ischemic cardiomyopathy.⁹ Participants received intravenous NAD+ or placebo for seven days alongside guideline-directed cardiac care.⁹ This was a defined hospital population, not a general wellness group.⁹

At one month, the NAD+ group had a statistically greater improvement in left ventricular ejection fraction, a measure of cardiac pumping function.¹⁰ Several secondary comparisons, including the combined clinical-event measure, remained nonsignificant trends.¹⁰ The authors called for validation in larger multicenter trials focused on clinical endpoints.¹⁰

The positive primary result belongs to that disease, setting, care plan, endpoint, and follow-up.¹⁰ It cannot be converted into proof of more energy, sharper thinking, better recovery, or slower aging for healthy lounge customers.⁹

MOTS-c is named here only as the neutral catalog reference below.

Tolerability and sterility are different questions

The 2019 pilot reported no observable adverse events during its short observation window.¹¹ Only eight men received NAD+, so that finding cannot map uncommon reactions or longer-term safety.¹¹ A later commercial-setting review adds a different, still preliminary view.¹²

That retrospective study included six NAD+ clients and eight NR clients.¹² NAD+ recipients reported gastrointestinal symptoms, faster heart rate, and chest pressure during infusions.¹² The symptoms resolved when the infusions ended.¹² The review was small, nonrandomized, and not built to prove effectiveness.¹²

Product quality sits beside tolerability, not inside it.⁴ The U.S. FDA warned that food-grade NAD+ was unsuitable for sterile compounding without appropriate processing.⁴ It also reported severe chills, shaking, vomiting, and fatigue after NAD+ products, sometimes requiring medical care.⁴ That warning describes U.S. compounding concerns, not Philippine regulatory status.⁴

A Philippines-ready way to check the pitch

For Filipino readers, the first useful question is exact: what outcome is being promised?⁵ “Supports cellular energy” describes a mechanism, while “you will feel energized” predicts a personal result.¹ Ask which human study measured that result, with what comparator, in what population, and for how long.⁵

Next, match the evidence to the route.³ Oral NR, oral NMN, and intravenous NAD+ are related research lanes, not interchangeable proof.³ A heart-failure trial cannot validate a broad wellness promise for healthy customers.⁹ A blood change cannot answer a question about focus or fatigue unless those outcomes were also measured.⁷

For an exact drug-product check, the Philippine FDA Verification Portal lists registration number, name, dosage form, manufacturer, issuance date, and expiry date.¹³ Match the exact named product and form rather than assuming that a molecule-wide claim covers every clinic offering.¹³

Bottom line

The marketing story starts with a true but incomplete fact: NAD+ matters in cellular energy metabolism.¹ Direct IV research shows how infused NAD+ moves through plasma and urine, but that pilot did not measure the headline wellness outcomes.² Oral-precursor trials show that a higher NAD-related biomarker can coexist with unchanged cognition, fatigue, sleep, or mood.⁷ A positive cardiac finding also stays inside its hospital population and protocol.¹⁰

The fairest verdict is claim by claim.⁵ Look for a human outcome that matches the promise, route, population, and follow-up.⁵ Then consider short-term tolerability and sterile-product quality as separate questions.¹² Biology makes the research plausible; only the matching human endpoint can make the marketing accurate.³

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

What is NAD+ in plain language?

NAD+ is a coenzyme that takes part in cellular energy metabolism and supports reactions run by several enzyme systems.¹ Calling it essential explains why scientists study it.¹ It does not establish that an infusion improves a person’s energy, cognition, recovery, or pace of aging.¹

Did the direct IV pilot show more energy?

The 2019 pilot followed plasma and urine metabolites in eight healthy men receiving NAD+ and three receiving saline.² Its measured results concerned metabolic handling over eight hours.⁶ Energy, focus, recovery, and anti-aging outcomes were outside that study’s tested endpoints.²

If blood NAD+ rises, does that mean the intervention worked?

It shows biochemical target engagement when the study measures a rise correctly.³ It does not automatically show a felt or functional benefit.³ In a small cognitive trial, oral NR raised blood NAD+ 2.6-fold while cognition remained unchanged over ten weeks.⁷

Does the heart-failure trial support wellness marketing?

The trial supports a narrow finding in 180 adults with heart failure caused by ischemic cardiomyopathy.⁹ Its primary cardiac-function result favored NAD+ at one month, while several secondary comparisons remained nonsignificant trends.¹⁰ That setting does not match a healthy customer seeking general wellness.⁹

What can a Filipino reader verify locally?

The Philippine FDA Verification Portal can be searched using an exact drug name or registration detail.¹³ Its records show fields such as dosage form, manufacturer, issuance date, and expiry date.¹³ A matching entry concerns the named product; it does not prove every broader clinic claim.¹³

What safety detail is easy to miss?

Tolerability during an infusion and sterile-product quality are separate issues.¹² A small commercial review recorded temporary gastrointestinal symptoms, faster heart rate, and chest pressure among NAD+ recipients.¹² The U.S. FDA separately warned about contamination risks when unsuitable NAD+ ingredients enter sterile compounding.⁴

Sources

Footnotes

1. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.. Review of human research on NAD+-boosting compounds. A central biological role does not establish that adding NAD+ by infusion improves energy, aging, or wellness outcomes. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

2. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD.. Small controlled human pharmacokinetic and metabolomic pilot. The study was designed around metabolic fate, not energy, cognition, recovery, or anti-aging outcomes. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

3. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.; Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.. Systematic review and clinical-literature review of NAD precursor interventions. Oral precursors are not interchangeable with intravenous NAD+, and the reviewed populations and measures varied. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶

4. FDA reminds compounders to use ingredients suitable for sterile compounding. U.S. federal safety communication about ingredients used for sterile compounding. This warning addresses U.S. compounding and does not determine Philippine regulatory status or describe every infusion product. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.. PRISMA-guided review of human and rodent NAD-related interventions published from 2010 through October 2025. The review's eligibility rules and search dates define this statement; it is not a claim that other research records cannot exist. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

6. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD.. Serial plasma and urine measurements during and after intravenous infusion. Movement through plasma and urine is a pharmacokinetic finding, not a demonstrated wellness benefit. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

7. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.. Small placebo-controlled pilot focused primarily on safety, with cognition as a measured outcome. This study tested an oral precursor in a clinical population, not intravenous NAD+ in healthy lounge customers. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

8. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial.. Single-center double-blind randomized trial with a placebo lead-in phase. Dropout was substantial, and exploratory within-group changes do not replace the randomized comparison. ↩ ↩² ↩³ ↩⁴ ↩⁵

9. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.. Randomized placebo-controlled disease-treatment trial in adults with impaired cardiac function. A hospital study in a defined disease population does not establish a general energy, recovery, or anti-aging result. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

10. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.. One-month primary cardiac-function endpoint and six-month secondary clinical endpoints. The single-center finding requires validation and cannot be transferred to healthy wellness customers. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

11. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD.. Eight-hour safety observations and laboratory measurements in a very small healthy-male cohort. A small, short pilot cannot characterize uncommon reactions or longer-term safety. ↩ ↩²

12. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting.. Electronic-record review after four consecutive infusion days with 30-day follow-up. The study was small, nonrandomized, retrospective, and not designed to demonstrate clinical effectiveness. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

13. FDA Verification Portal: All Drug Products. Official Philippine regulatory database interface. A search result must be matched to the exact named product and dosage form; the portal does not validate broad clinic marketing claims. ↩ ↩² ↩³ ↩⁴ ↩⁵